-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SYNCAR-001 in Non-Hodgkin Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SYNCAR-001 in Non-Hodgkin Lymphoma Drug Details: SYNCAR-001 is under development for the treatment of unspecified B-cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SYNCAR-001 in Relapsed Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SYNCAR-001 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details: SYNCAR-001 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SYNCAR-001 in Refractory Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SYNCAR-001 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details: SYNCAR-001 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Atuzabrutinib in Allergies
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Atuzabrutinib in AllergiesDrug Details:Atuzabrutinib (PRN-473) is under development for the treatment of hepatic injury, mild to...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tarperprumig in Sickle Cell Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tarperprumig in Sickle Cell Disease Drug Details: Tarperprumig (ALXN-1820) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Decitabine in Metastatic Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Decitabine in Metastatic Breast CancerDrug Details:Decitabine (DW-1018) is under development for the treatment of HER2 negative...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STK-012 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.STK-012 in Solid Tumor Drug Details:STK-012 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – M-701 in Malignant Pleural Effusion
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. M-701 in Malignant Pleural Effusion Drug Details: M-701 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 2-CCPA in Osteoarthritis Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.2-CCPA in Osteoarthritis PainDrug Details:2-CCPA is under development for osteoarthritis pain of knee. It is a synthetic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STK-012 in Renal Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STK-012 in Renal Cell Carcinoma Drug Details: STK-012 is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.